ArticleJournal of robotic surgery2025
Demonstrating the non-inferiority of robotic radical cystectomy for cT3-cT4 urothelial carcinoma in the era of neoadjuvant chemotherapy: a propensity score-matched analysis.
Article in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated whether robot-assisted radical cystectomy (RARC) is non-inferior to open radical cystectomy (ORC) in patients with cT3-cT4 urothelial carcinoma receiving cisplatin-based neoadjuvant chemotherapy (NAC). We retrospectively analyzed 204 patients (ORC = 123, RARC = 81) across 11 centers. A 1:1 propensity score matching based on age, sex, T stage, and nodal status minimized the selection bias. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were compared using Kaplan-Meier analyses and log-rank tests. Cox regression identified independent prognostic factors. Before PSM, the RARC group included younger patients and had fewer individuals with cT4 tumors. Following PSM, 81 patients remained in each arm with balanced characteristics. RARC and ORC showed similar RFS (log-rank p = 0.90) and CSS (p = 0.16), whereas OS slightly favored RARC (p = 0.049). In a multivariable analysis, the surgical approach did not independently predict oncologic outcomes; instead, advanced pathologic stage (≥ pT2), lymphovascular invasion, and nodal involvement (≥ N1) were significant risk factors. The operative time was longer, but blood loss was lower in RARC, with no significant difference in positive margins or major complications. RARC demonstrated non-inferior oncologic outcomes compared to ORC in patients with cT3-cT4 urothelial carcinoma treated with NAC. These findings support the feasibility of a minimally invasive approach without compromising efficacy in advanced bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.